Elke Birkemeyer

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Staffan Welin, Seppo W. Langer, Lene Weber Vestermark et al. · Annals of Oncology · 2012 · 1K citations

Medicine, Oncology, Surgery +12

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Kjell Magne Tveit, Tormod Kyrre Guren, Bengt Glimelius et al. · Journal of Clinical Oncology · 2012 · 530 citations

Medicine, Oncology, Pharmacology +16

Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer

Morten Brændengen, Kjell M. Tveit, Åke Berglund et al. · Journal of Clinical Oncology · 2008 · 480 citations · Full text

Medicine, Oncology, Surgery +15

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

Satu Oltedal, Ole Gunnar Aasprong, Jannicke Horjen Møller et al. · International Journal of Colorectal Disease · 2011 · 41 citations

Medicine, Oncology, Pathology +17

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study.

Halfdan Sørbye, Staffan Welin, Seppo W. Langer et al. · Journal of Clinical Oncology · 2012 · 11 citations

Medicine, Oncology, Pathology +17